MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jne.13349

Медицинская библиотека · Journal of neuroendocrinology · 2023

Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.

Tang Charlene Yu Lin, Chua Wei Ming, Huang Hian Liang, Lam Winnie Wing-Chuen, Loh Lih Ming, Tai David, Ong Simon Yew Kuang, Yan Sean Xuexian, Loke Kelvin S H, Ng David Chee-Eng, Tham Wei Ying

Систематический обзорСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Despite advances in diagnosis and management, patients with advanced pheochromocytomas and paragangliomas (PPGL) face limited treatment options. This study aims to evaluate the safety and efficacy of peptide receptor radionuclide therapy (PRRT) in patients with advanced PPGL, based on a single-institution experience and provide a comprehensive review of the literature.

METHODS

A retrospective analysis was conducted on patients with advanced pheochromocytoma and paraganglioma who received PRRT at a single institution from April 2012 to March 2022. Clinical characteristics, treatment response, adverse events, and survival outcomes were assessed. A systematic literature review was also performed.

RESULTS

A total of 15 patients with advanced PPGL were included, the majority of whom had both metastatic and functional disease. Most patients received four infusions of 177Lu-DOTATATE (73%). The median therapeutic 177Lu-DOTATATE radioactivity for each infusion was 7.4 GBq. Only one patient was treated with one infusion of 90Y-DOTATATE (4.2 GBq) in addition to three infusions of Lu-177 DOTATATE. Overall, PRRT suggests a promising efficacy with disease control rate of 63.6% by RECIST v1.1. The median overall survival (OS) was not reached and the median progression free survival (PFS) was 25.9 months. In terms of safety, PRRT was well tolerated. Review of the literature revealed consistent findings, supporting the efficacy and safety of PRRT in PPGL.

CONCLUSION

This study suggests that PRRT is a safe and effective therapeutic option for patients with PPGL. Our findings align with the existing literature, providing additional evidence to support the use of PRRT in this challenging patient population.

Для цитирования: Tang Charlene Yu Lin, Chua Wei Ming, Huang Hian Liang, Lam Winnie Wing-Chuen, Loh Lih Ming, Tai David, Ong Simon Yew Kuang, Yan Sean Xuexian, Loke Kelvin S H, Ng David Chee-Eng, Tham Wei Ying. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.. Journal of neuroendocrinology. 2023. DOI: 10.1111/jne.13349.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.